Chiasma announces commercial supply agreement with Lonza for Mycapssa
Chiasma and Lonza announced that the companies have entered into a commercial supply agreement for Chiasma's oral somatostatin analog candidate, conditionally trade named Mycapssa. Chiasma is conducting a Phase 3 clinical trial under a special protocol assessment agreement reached with the FDA for its octreotide capsules product candidate, Mycapssa, for the maintenance therapy of adult patients with acromegaly. If approved, Chiasma believes Mycapssa will be the first oral somatostatin analog for the treatment of acromegaly, a disorder that typically develops when a benign tumor of the pituitary gland produces too much growth hormone. Chiasma and Lonza have signed a manufacturing contract to support the anticipated launch and ongoing commercial supply of Mycapssa at Lonza's Edinburgh site. The agreement extends a collaboration between the two companies that has been in place since 2012. Octreotide acetate is currently only available by injection for patients suffering from acromegaly. Mycappsa uses Chiasma's proprietary technology to produce the octreotide capsules formulation manufactured using Lonza's liquid-filled hard capsule technology. As part of the collaboration, Chiasma and Lonza jointly invested in specialized milling equipment, large-scale LFHC coating equipment and in-house printing capabilities to support the processing, filling and other manufacturing activities performed by Lonza for Mycappsa manufacturing.